Patent Claims

We Claim:

1. A compound of the formula I,

5 wherein,

> R^{0} is 1) a monocyclic or bicyclic 6- to 14-membered aryl, wherein, the aryl is mono-, di- or trisubstituted independently of one another by R8,

10

2) a monocyclic or bicyclic 4- to 15-membered heterocyclyl, selected from the group consisting of acridinyl, azaindole, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, 1,3-benzodioxolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-

15

dihydrooxazolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl,

imidazolinyl, imidazolyl, indazolyl, indolinyl, indolizinyl, indolyl, , isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolyl, isothiazolyl,

20

isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl,

oxadiazolyl, 1,2-oxathiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, oxetanyl, oxocanyl, phenanthridinyl,

25

phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phenylpyridyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl,

pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyridooxazolyl,

pyridoimidazolyl, pyridothiazolyl, pyridyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolyl,

4H-quinolizinyl, quinoxalinyl, 1,4,5,6-tetrahydropyridazinyl, quinuclidinyl,

tetrahydrofuranyl, tetrahydroisoguinolinyl, tetrahydroguinolinyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl,

thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-

thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl,

thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl,

thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,3,4-triazolyl, xanthenyl, or

5

a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from the group consisting of nitrogen, sulfur or oxygen, wherein, said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

10

- R8 is 1) halogen,
 - 2) -NO₂,
 - 3) -CN,
 - 4) $-C(O)-NH_2$,

15

- 5) -OH,
- 6) $-NH_2$,
- 7) –O-CF₃
- 8) a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, dior trisubstituted independently of one another by halogen or $-O-(C_1-C_8)$ -alkyl,

20

- 9) -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue,
- 10) $-O-(C_1-C_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue,

25

- 11) -SO₂-CH₃ or
- 12) -SO₂-CF₃,

provided that where R^0 is a monocyclic or bicyclic 6- to 14-membered aryl, then R8 is at least one halogen, $-C(O)-NH_2$ or $-O-(C_1-C_8)$ -alkyl residue;

30

Q is a direct bond, -(C₀ -C₂)-alkylene-C(O)-NR¹⁰-, -NR¹⁰-C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -(C₁-C₆)-alkylene, -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-C(O)-

 $(CH_2)_{n^-}, -(CH_2)_{m^-}S-(CH_2)_{n^-}, -(CH_2)_{m^-}C(O)-(CH_2)_{n^-}, -(CH_2)_{m^-}SO_2-NR^{10}-(CH_2)_{n^-}, -(CH_2)_{m^-}NR^{10}-SO_2-(CH_2)_{n^-}, -(CH_2)_{m^-}NR^{10}-SO_2-NR^{10}-(CH_2)_{n^-}, -(CH_2)_{m^-}CH(OH)-(CH_2)_{n^-}, -(CH_2)_{m^-}O-C(O)-NR^{10}-(CH_2)_{n^-}, -(C_2-C_3)-alkylene-O-(C_0-C_3)-alkylene-, -(C_2-C_3)-alkylene-S(O)_2-, -(CH_2)_{m^-}NR^{10}-C(O)-O-C(CH_2)_{n^-}, -(C_2-C_3)-alkylene-S(O)_2-NH-(R^{10})_{n^-}, -(C_2-C_3)-alkylene-N(R^{10})_{n^-} or -(C_0-C_3)-alkylene-C(O)-O-,$

wherein R^{10} is as defined below, and wherein n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6, wherein the alkylene residues which are formed by $-(CH_2)_m$ - or $-(CH_2)_n$ - are unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $-NH_2$ or -OH; or $-(C_3-C_6)$ -cycloalkylene, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $-NH_2$ or -OH;

- hydrogen, -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13; -(C₁-C₃)-alkylene-C(O)-NH-R⁰, -(C₁-C₃)-alkylene-C(O)-O-R10, a monocyclic or bicyclic 6- to 14-membered aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R8, a monocyclic or bicyclic 4- to 15-membered heterocyclyl, containing one, two, three or four heteroatoms chosen from nitrogen, sulfur or oxygen; -(C₁-C₃)-perfluoroalkyl,

 -(C₁-C₃)-alkylene-S(O)-(C₁-C₄)-alkyl, -(C₁-C₃)-alkylene-S(O)₂-(C₁-C₃)-alkyl,

 -(C₁-C₃)-alkylene-S(O)₂-N(R⁴')-R⁵', -(C₁-C₃)-alkylene-O-(C₁-C₄)-alkyl,

 -(C₀-C₃)-alkylene-(C₃-C₈)-cycloalkyl, or -(C₀-C₃)-alkylene-het, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, and;
- 25 R^4 ' and R^5 ' are independent of one another are identical or different and are hydrogen or -(C_1 - C_4)-alkyl;
 - R^2 is a direct bond or $-(C_1-C_4)$ -alkylene, or
- 30 R¹ and R3 together with the atoms to which they are bonded form a 6- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, and wherein, said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14; or

R¹-N-R²-V form a 4- to 8-membered cyclic group, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

5

15

10

V is 1) a 3- to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

20

 a 6- to14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

_ _

 a monocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

25

G is a direct bond, $-(CH_2)_m - NR^{10} - SO_2 - NR^{10} - (CH_2)_n - (CH_2)_m - CH(OH) - (CH_2)_n - (CH_2)_m - (CH_2)_$

30

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6;

| | M is | 1) hydro | ogen, |
|---|-------------------|--|--|
| | | 2) -(C ₁ - | C ₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted |
| | | independently of one another by R14, | |
| | | 3) -C(O |)-N(R11)-R12, |
| 5 | | 4) -(CH | ₂) _m -NR ¹⁰ , |
| | | 5) a 6- t | o14-membered aryl, wherein aryl is unsubstituted or mono-, di- or |
| | | trisubstituted | independently of one another by R14, |
| | | 6) a mo | nocyclic or bicyclic 4- to 15-membered heterocyclyl, wherein |
| | | heterocyclyl | is unsubstituted or mono-, di- or trisubstituted independently of one |
| 10 | another by R14, | | |
| | | 7) -(C ₃ - | C ₈)-cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or |
| | | trisubstituted | independently of one another by R14, or |
| | | 8) a 3-1 | to 7-membered cyclic residue, containing 1, 2, 3 or 4 heteroatoms chosen |
| | | from | nitrogen, sulfur or oxygen, wherein said cyclic residue is unsubstituted |
| 15 | | or m | ono-, di- or trisubstituted independently of one another by R14; |
| | | | |
| | R ³ an | d R ⁴ are indepe | endent of one another are identical or different and are |
| | 1) | hydrogen, | |
| | 2) | halogen, | |
| 20 | 3) | $-(C_1-C_4)$ -alk | yl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted |
| | | independentl | y of one another by R13, |
| | 4) | -(C ₁ -C ₃)-per | fluoroalkyl, |
| | 5) | phenyl, where | ein phenyl is unsubstituted or mono-, di- or trisubstituted independently |
| | | of one anothe | er by R13, |
| 25 6) -(C ₀ -C ₄)- | | $-(C_0-C_4)$ -alk | ylene-O-R19, wherein R19 is |
| | | a) | hydrogen, |
| | | b) | -(C_1 - C_4)-alkyl, wherein alkyl is unsubstituted or mono-, di- or |
| | | | trisubstituted independently of one another by R13, or |
| | | c) | phenyl, wherein phenyl is unsubstituted or mono-, di- or |
| 30 | | | trisubstituted independently of one another by R13, |
| | | d) | -CF ₃ , or |
| | | e) | -CHF ₂ , |
| | 7) | -NO ₂ , | |
| | 8) | -CN, | |
| | | | |

9) $-SO_s-R^{11}$, wherein s is 1 or 2,

10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,

- 11) $-(C_0-C_4)$ -alkylene-C(O)-R¹¹,
- 12) $-(C_0-C_4)$ -alkylene-C(O)-O-R¹¹,
- 13) $-(C_0-C_4)$ -alkylene-C(O)-N(R¹¹)-R¹²,
- 5 $-(C_0-C_4)$ -alkylene- $N(R^{11})$ - R^{12} ,
 - 15) $-NR^{10}-SO_2-R^{10}$,
 - 16) $-S-R^{10}$,

- - (C_0-C_2) alkylene- $C(O)-O-(C_2-C_4)$ -alkylene- $O-C(O)-(C_1-C_4)$ -alkyl,
- 18) -C(O)-O-C(R15, R16)-O-C(O)-R17,
- 10 19) $-(C_0-C_2)$ alkylene- $C(O)-O-(C_2-C_4)$ -alkylene- $O-C(O)-O-(C_1-C_6)$ -alkyl,
 - 20) -C(O)-O-C(R15, R16)-O-C(O)-O-R17,
 - -(C_0 - C_4)-alkylene-(C_6 - C_{14})-aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R13,
 - -(C₀-C₄)-alkylene-(C₄-C₁₅)-heterocyclyl, wherein heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13
 - -(C₀-C₄)-alkylene-(C₃-C₈)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - -(C₀-C₄)-alkylene-het, wherein het is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- $20 \qquad \qquad \text{25)} \qquad \text{-(C_0-C_4)-alkylene-O-CH$_2$-(C_1-C_3)-perfluoroalkylene-CH$_2$-O-(C_0-C_4)-alkylene-CH$_2$-(C_1-C_3)-perfluoroalkylene-CH$_2$-(C_0-C_4)-alkylene-CH$_2$-(C_1-C_3)-perfluoroalkylene-CH$_2$-(C_0-C_4)-alkylene-CH$_2$-(C_1-C_3)-perfluoroalkylene-CH$_2$-(C_0-C_4)-alkylene-CH$_2$-(C_0-C_0-C_0-C_0)-alkylene-CH$_2$-(C_0-C_0-C_0)-alkylene-CH$_2$-(C_0-C_0-C_0)-alkylene-CH$_2$-(C_0-C_0-C_0)-alkylene-CH$_2$-(C_0-C_0)-alkylene-CH$_2$-(C_0-C_0)-alkylene-CH$_2$-(C_0-C_0)-alkylene-CH$_2$-(C_0-C_0)-alkylene-CH$_2$-(C_0-C_0)-alkylene-CH$_2$-(C_0-C_0)-alkylene-CH$_2$-(C_0-C_0)-alkylene-CH$_2$-($C_$
 - 26) a residue selected from the group consisting of

wherein Me is methyl, or

two -OR19 residues and adjacent atoms through which they are attached form together a 5- or 6- membered ring, that is unsubstituted or substituted one, two, three or four times by R13;

R11 and R12 are independently of one another identical or different and are

10

- 1) hydrogen,
- 2) -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)$ -alkyl- (C_3-C_8) -cycloalkyl,
- 4) $-SO_t-R^{10}$, wherein t is 1 or 2,

15

- 5) -(C₀-C₆)-alkyl-(C₆-C₁₄)-aryl, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13,
- 6) -(C₁-C₃)-perfluoroalkyl,
- 7) $-O-R^{17}$, or
- 8) $-(C_0\text{-}C_6)\text{-alkyl-}(C_4\text{-}C_{15})\text{-heterocyclyl, wherein alkyl and heterocyclyl}$

independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or

20

25

30

R11 and R12 together with the nitrogen atom to which they are bonded can form a 4- to 8membered monocyclic heterocyclic ring which in addition to the nitrogen atom can
contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur
and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or
trisubstituted independently of one another by R13;

R13 is halogen, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₃-C₈)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -N(R¹⁰)-S(O)_u-R¹⁰,

wherein u is 1 or 2, -S-R¹⁰, -SO_r-R¹⁰, wherein r is 1 or 2, -S(O)_v-N(R¹⁰)-R²⁰, wherein v is 1 or 2, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenyloxy-, -O-CF₃, -(C₀-C₄)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-R17, -(C₁-C₄)-alkoxy-phenyl, -(C₀-C₄)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-O-R17, -(C₁-C₃)-perfluoroalkyl, -O-R15, -NH-C(O)-NH-R¹⁰, -NH-C(O)-O-R¹⁰, or a residue selected from the group consisting of

10

15

5

 $R^{10} \text{ and } R^{20} \text{ are independently of one another hydrogen, -(C$_1$-C$_6$)-alkyl,} \\ -(C_0$-C_4$)-alkyl-OH, -(C_0$-C_4$)-alkyl-O-(C_1$-C_4$)-akyl or -(C_1$-C_3$)-perfluoroalkyl;}$

R15 and R16 are independently of one another hydrogen, $-(C_1-C_6)$ -alkyl, or together with the carbon atom to which they are bonded they can form a 3- to 6 membered carbocyclic ring which is unsubstituted or substituted one to three times by R¹⁰; and

R17 is $-(C_1-C_6)$ -alkyl, $-(C_1-C_6)$ -alkyl-OH, $-(C_1-C_6)$ -alkyl-O- $-(C_1-C_6)$ -alkyl, $-(C_3-C_8)$ -cycloalkyl, $-(C_1-C_6)$ -alkyl-O- $-(C_1-C_8)$ -alkyl- $-(C_3-C_8)$ -cycloalkyl, wherein said cycloalkyl ring is unsubstituted or substituted one, two or three times by -OH, $-O-(C_1-C_4)$ -alkyl or R^{10} ; or

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically

tolerable salts.

2. The compound according to claim 1, wherein,

R⁰ as 2) is benzothiophenyl, indazolyl, indolyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pyridyl, pyrimidinyl, quinazolinyl or quinolyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

 R^3 and R^4 as

and

 $25) is - (C_0-C_3)-alkylene-O-CH_2-(C_1-C_3)-perfluoroalkylene-CH_2-O-(C_0-C_3)-alkyl;\\$

10

5

 R^{10} and R^{20} are independently of one another hydrogen, -(C₁-C₆)-alkyl or -(C₁-C₃)-perfluoroalkyl.

3. The compound according to claim 1, wherein,

15

 R^0 as 1) is phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, that is mono-, di- or trisubstituted independently of one another by R8,

20

2) is a heterocyclyl out of the group benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or

25

is acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolinyl, isoxazolinyl, isoxazolinyl, 2-isoxazolinyl,

30

ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoguinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxathiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, 1,2-oxazinyl, 1,3oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thiazolyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl,

20

5

10

15

25

30

35

that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and which is additionally substituted by acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5-dihydrooxazolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, 1,2oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl,

pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenolyl, thiophenyl, thiopyranyl, 1,2,3-triazinyl, 1,2,4-triazinyl, 1,3,5-triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

 R^{1} as $-(C_{6}-C_{14})$ -aryl is phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, that is mono-, dior trisubstituted independently of one another by R8, or

15

5

10

-(C₀-C₃)-alkylene-het, then het is azepine, azetidine, aziridine, azirine, 1,4-diazapane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazoline, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazolidine, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrrolidine, tetrahydropyridine, tetrazine, tetrazole, thiadiazine thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

25

30

20

R¹ and R3 together with the atoms to which they are bonded form azocane, azocane-2-one, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, [1,4]diazocane, [1,2]diazocan-3-one, [1,3]diazocan-2-one, dioxazine, [1,4]dioxocane, dioxole, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, [1,4]oxazocane, [1,3]oxazocan-2-one, oxocane, oxocane, piperazine, piperidine, pyran, pyrazine, pyridazine, pyrimidine or 5,6,7,8-tetrahydro-1H-azocin-2-one, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

R14 as -(C₀-C₄)-alkyl-het, then het is azetidine, azetidinone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4diazepine, azepine, ketopiperazine, 1,4-oxazepane, oxazole, isoxazole, isoxazolidine, 2isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine;

V is 2) wherein the aryl is phenyl, naphthyl, biphenylyl, anthryl or fluorenyl, that is mono-, di- or trisubstituted independently of one another by R14, or

10

5

4) wherein the heterocyclyl is acridinyl, azaindole, 1H-pyrrolopyridine, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl,

15

chromenyl, cinnolinyl, decahydrochinolinyl, 1,4-diazepane, 4,5-dihydrooxazolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl,

imidazolidinyl, imidazolyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl,

20

25

30

indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl,

isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl,

ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoguinolinyl,

oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-

oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-

oxazepinyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl, oxazolidinyl,

oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl,

phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl,

piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl,

pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl,

pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-

pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl,

quinuclidinyl, tetrahydrofuranyl, tetrahydroisochinolinyl,

tetrahydrochinolinyl, 1,4,5,6-tetrahydro-pyridazinyl, tetrahydropyridinyl,

tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-

thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl,

thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolidinyl, thiazolinyl, thienyl, thietanyl, thienothiazolyl,

thienooxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl or xanthenyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

5

- M is 1) hydrogen,
 - 2) -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

10

- 3) -C(O)-N(R11)-R12,
- 4) $-(CH_2)_m-NR^{10}$,
- 5) $-(C_6-C_{14})$ -aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
- 6) $-(C_4-C_{15})$ -heterocyclyl, wherein heterocyclyl is unsubstituted or mono-, dior trisubstituted independently of one another by R14, or
- 7) -(C₃-C₈)-cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

 R^3 and R^4 as

20

15

5) $-(C_0-C_4)$ -alkylene-O-R19, or

two -OR19 residues and adjacent atoms through which they are attached form together a 5- or 6- membered ring, that is unsubstituted or substituted one, two, three or four times by R13;

25

R11 and R12 together with the nitrogen atom to which they are bonded form azepine, azetidine, dioxazole, dioxazine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, 1,4-oxazepine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazolidine, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R13; and

30

R15 and R16 are independently of one another hydrogen, -(C_1 - C_6)-alkyl, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R^{10} .

- 5 4. The compound according to claim 1, wherein,
 - R⁰ as 1) is phenyl, naphthyl, biphenyl, anthryl or fluorenyl, that is mono-, di- or trisubstituted independently of one another by R8,
 - 2) is benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl, purinyl, pyridyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyridazinyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or
 - 3) is azabenzimidazolyl, benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxazolyl, chromanyl, cinnolinyl, 2-furyl, 3furyl; imidazolyl, indolyl, indazolyl, isochromanyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl, oxazolyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, 2pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl, pyrrolyl; 2-pyrrolyl, 3-pyrrolyl, quinolinyl, quinazolinyl, quinoxalinyl, tetrazolyl, thiazolyl, 2-thienyl or 3-thienyl, which is additionally substituted by a heterocyclyl selected out of the group acridinyl, azabenzimidazolyl, azaspirodecanyl, azepinyl, azetidinyl, aziridinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aHcarbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydrochinolinyl, 4,5dihydrooxa-zolinyl, dioxazolyl, dioxazinyl, 1,3-dioxolanyl, 1,3-dioxolenyl, 6H-1,5,2dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuranyl, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolinyl, indolizinyl, indolyl, 3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isothiazolidinyl, isothiazolinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, 2-isoxazolinyl, ketopiperazinyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2-oxa-thiepanyl, 1,2-oxathiolanyl, 1,4-oxazepanyl, 1,4-oxazepinyl, 1,2-oxazinyl, 1,3-oxazinyl, 1,4-oxazinyl,

20

15

10

25

30

10

15

25

30

35

oxazolidinyl, oxazolinyl, oxazolyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, purinyl, pyrazolyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridoxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolidinonyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, atterahydrofuranyl, tetrahydroisochinolinyl, tetrahydrochinolinyl, 1,4,5,6-tetrahydropyridazinyl, tetrahydropyridinyl, tetrahydrothiophenyl, tetrazinyl, tetrazolyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, 1,2-thiazinyl, 1,3-thiazinyl, 1,4-thiazinyl, 1,3-thiazolyl, thiazolyl, thiazolinyl, thienyl, thienyl, thienothiazolyl, thienoxazolyl, thienoimidazolyl, thietanyl, thiomorpholinyl, thiophenyl, thiopyranyl, 1,2,3-triazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl and xanthenyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

R8 as 1. is fluorine, chlorine or bromine, provided that R8 is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue;

Q is a direct bond, -(C_0 - C_2)-alkylene-C(O)-NR¹⁰-, -NR¹⁰-C(O)-NR¹⁰-, -NR¹⁰-, -NR¹⁰-C(O)-NR¹⁰-, -NR¹⁰-, -NR¹⁰

R¹ is hydrogen, -(C_1 - C_4)-alkyl, wherein alkyl is unsubstituted or substituted one to three times by R13; -(C_1 - C_3)-alkylene-C(O)-NH-R⁰, -(C_1 - C_3)-alkylene-C(O)-O-R10, -(C_1 - C_3)-perfluoroalkyl, -(C_1 - C_3)-alkylene-S(O)-(C_1 - C_4)-alkyl, -(C_1 - C_3)-alkylene-S(O)₂-(C_1 - C_3)-alkylene-S(O)₂-N(R⁴')-R⁵', -(C_1 - C_3)-alkylene-O-(C_1 - C_4)-alkyl, -(C_0 - C_3)-alkylene-(C_3 - C_8)-cycloalkyl, or -(C_0 - C_3)-alkylene-het, wherein het is azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazolidine, isothiazolidine, isothiazoline, isoxazoline, isoxazoline, isoxazoline, etopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,4-oxazepine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyrazole, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrabydropyridine, tetrazole, thiadiazine

thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazolidine, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

5

R¹-N-R²-V form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, 1,4-oxazepane, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyridine, pyrrole, pyrrolidine, pyrrolidine, pyrrolidine, tetrahydropyridine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

15

10

R14 is fluorine, chlorine, bromine, iodine, -OH, =O, -(C $_1$ -C $_8$)-alkyl, -(C $_1$ -C $_4$)-alkoxy, -NO $_2$, -C(O)-OH, -CN, -NH $_2$, -C(O)-O-(C $_1$ -C $_4$)-alkyl, -(C $_1$ -C $_8$)-alkylsulfonyl, -SO $_2$ -N-(R¹⁸)-R²¹, -C(O)-NH-(C $_1$ -C $_8$)-alkyl, -C(O)-N-[(C $_1$ -C $_8$)-alkyl] $_2$, -NR¹⁸-C(O)-NH-(C $_1$ -C $_8$)-alkyl, -C(O)-NH $_2$, -S-R¹⁸, or -NR¹⁸-C(O)-NH-[(C $_1$ -C $_8$)-alkyl] $_2$, wherein R¹⁸ and R²¹ are independently from each other hydrogen atom, -(C $_1$ -C $_3$)-perfluoroalkyl or -(C $_1$ -C $_6$)-alkyl;

20

V is 3) wherein the 4- to 15-membered heterocyclyl is azaindole, 1H-pyrrolopyridine, azepine, azetidine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diaziridine, diazirine, dioxazole, dioxazine, dioxole, 1,3-dioxolene, 1,3-dioxolane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazoline, 2-isoxazoline, ketopiperazine, morpholine, 1,2-oxa-thiepane, 1,2-oxathiolane, 1,4-oxazepane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, oxaziridine, oxirane, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiadiazine, thiadiazole, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thiazole, thiazoline, thiazoline, thienyl, thietan, thiomorpholine, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

30

- 2) phenyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;
- M is 1) hydrogen,
 - 2) -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
 - 3) -C(O)-N(R11)-R12,
 - 4) $-(CH_2)_m-NR^{10}$,
 - 5) phenyl or naphthyl, wherein phenyl or naphthyl are unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
 - heterocyclyl, wherein heterocyclyl is a residue out of the group which can be derived from azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-isoxazoline, ketomorpholine, ketopiperazine, morpholine, oxazole, [1,4]-oxazepane, piperazine, piperazinone, piperidine, piperidinone, pyrazine, pyridazine, pyridazinone, pyridine, pyridone, pyrimidine, pyrrolidine, pyrrolidinone, tetrahydropyran, 1,4,5,6-tetrahydropyridazinyl, tetrazine, tetrazole, thiadiazole, thiazole, thiophene, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or
- 7) -(C₃-C₈)-cycloalkyl, wherein said cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

 ${\rm R}^3$ and ${\rm R}^4$ are independent of one another are identical or different and are

- 1) hydrogen,
- 25 2) halogen,
 - 3) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13.
 - 4) -(C₁-C₃)-perfluoroalkyl,
 - 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - 6) $-(C_0-C_4)$ -alkylene-O-R19, wherein R19 is
 - a) hydrogen,
 - b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
 - phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,

10

5

15

20

25

30

- d) -CF₃, or
- e) CHF₂,
- 8) -CN,
- 9) $-SO_s-R^{11}$, wherein s is 1 or 2,
- 5 10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,
 - 11) $-(C_0-C_4)$ -alkylene-C(O)-R¹¹,
 - 12) $-(C_0-C_4)$ -alkylene-C(O)-O-R¹¹,
 - 13) $-(C_0-C_4)$ -alkylene-C(O)-N(R¹¹)-R¹²,
 - 14) $-(C_0-C_4)$ -alkylene-N(R¹¹)-R¹²,
- 10 15) -NR¹⁰-SO₂-R¹⁰,
 - -(C_0 - C_2)alkylene-C(O)-O-(C_2 - C_4)-alkylene-O-C(O)-(C_1 - C_4)-alkyl,
 - 18) -C(O)-O-C(R15, R16)-O-C(O)-R17,
 - 19) $-(C_0-C_2)$ alkylene- $C(O)-O-(C_2-C_4)$ -alkylene- $O-C(O)-O-(C_1-C_6)$ -alkyl,
 - 20) -C(O)-O-C(R15, R16)-O-C(O)-O-R17,
- 15 -(C₀-C₄)-alkylene-(C₆-C₁₄)-aryl, wherein aryl is mono-, di- or trisubstituted independently of one another by R13,
 - -(C₀-C₄)-alkylene-(C₃-C₈)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- -(C₀-C₃)-alkylene-O-CH₂-CF₂-CH₂-O-(C₀-C₃)-alkyl, -(C₀-C₃)-alkylene-O-CH₂-CF₂-CF₂-CH₂-O-(C₀-C₃)-alkyl, or -(C₀-C₃)-alkylene-O-CH₂-(C₁-C₃)-perfluoroalkylene-CH₂-OH, or
 - a residue selected from the group consisting of

wherein Me is methyl.

5 two -OR19 residues and adjacent atoms through which they are attached form together a 5- or 6- membered ring, that is unsubstituted or substituted one, two, three or four times by R13,

R11 and R12 are independently of one another identical or different and are

10 1) hydrogen,

- 2) -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)$ -alkyl- (C_6-C_{14}) -aryl, wherein aryl is as defined above and wherein alkyl and aryl are independently from one another unsubstituted or mono-, dior trisubstituted by R13,

7) $-O-R^{17}$, or

8) $-(C_0-C_6)$ -alkyl- (C_4-C_{15}) -heterocyclyl, wherein alkyl and heterocyclyl are independently from one another are unsubstituted or mono-, di- or trisubstituted by R13, or

20

25

30

15

R11 and R12 together with the nitrogen atom to which they are bonded form azepine, azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, isothiazole, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]oxazepane, 1,4-oxazepine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazolidine, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, pyrroline, tetrahydropyridine, tetrazine, tetrazole, thiazole, thiazole, thiazolidine, thiazoline, thiomorpholine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

10

15

25

R13 is fluorine, chlorine, bromine, iodine, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰,

-C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃,

 $-N(R^{10})-S(O)_2-R^{10}, -S-R^{10}, -SO_2-R^{10}, -S(O)_2-N(R^{10})-R^{20}, -C(O)-R^{10}, -(C_1-C_8)-R^{10}, -(C_1-C_8)-R^{1$

- (C_1-C_8) -alkoxy, phenyl, phenyloxy-, -O-CF₃, - (C_1-C_3) -perfluoroalkyl,

 $-(C_0-C_4)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-R17, -(C_1-C_4)-alkoxy-phenyl$

-(C₀-C₄)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-O-R17, -O-R15, -NH-C(O)-NH-R¹⁰,

-NH-C(O)-O-R¹⁰, or a residue from the following list

R15 and R16 are independently of one another hydrogen, -(C₁-C₆)-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, that is unsubstituted or substituted one to three times by R¹⁰.

- 5. The compound according to claim 1, wherein,
- 20 R0 as 1) is phenyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,
 - 2) is benzimidazolyl, 1,3-benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiophenyl, cinnolinyl, chromanyl, indazolyl, indolyl, isochromanyl, isoindolyl, isoquinolinyl, phenylpyridyl, phthalazinyl, pteridinyl,

purinyl, pyridinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyrimidinyl, quinazolinyl, quinolyl, quinoxalinyl or 1,4,5,6-tetrahydro-pyrid azinyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or

5

a heterocyclyl out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and in addition is substituted by a residue selected out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl or pyrazinyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

15

10

- R8 is 1. F, Cl, Br or I,
 - 4. $-C(O)-NH_2$,
 - 9. $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or a methoxy residue, or

20

10. -O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or a methoxy residue, provided that R8 is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue;

25

Q is a direct bond, -C(O)-; -SO₂-, -(C₁-C₆)-alkylene, or -(C₀-C₂)-alkylene-C(O)-NR¹⁰-;

 $\label{eq:R1} R^1 \mbox{ is } \mbox{ hydrogen, -(C$_1$-C$_2)-alkyl, -(C$_1$-C$_3)-alkylene-C(O)-NH-R$^0, -(C$_1$-C$_3)-perfluoroalkyl, -(C$_1$-C$_3)-alkylene-C(O)-O-R$^{10}, -(C$_1$-C$_3)-alkylene-S(O)$_2$-(C$_1$-C$_3)-alkylene-C(O)-N(R$^4')-R$^5',$ alkylene-S(O)\$_2\$-N(R\$^4')-R\$^5',

30

wherein R^4 ' and R^5 ' are independent of one another are identical or different and are hydrogen or -(C_1 - C_4)-alkyl;

R¹-N-R²-V forms azetidine, azetidinone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidine, pyrrolidine, pyrrolidine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazole, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine,

15

20

azepine, ketopiperazine, 1,4-oxazepane, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,

R14 is fluorine, chlorine, -OH, =O, -(C₁-C₈)-alkyl, -C(O)-OH, -CN, -NH₂,

 $-C(O)-O-(C_1-C_4)-alkyl, -C(O)-NH-(C_1-C_8)-alkyl, -C(O)-N-[(C_1-C_8)-alkyl]_2$

 $-C(O)-NH_2$ or $-N(R^{18})-R^{21}$,

wherein R^{18} and R^{21} are independently from each other hydrogen,

 $-(C_1-C_3)$ -perfluoroalkyl or $-(C_1-C_4)$ -alkyl;

V is 1. wherein the 3- to 7-membered cyclic residue is azaindole, 1H-

pyrrolopyridine, aziridine, azirine, azetidine, azetidinone, 1,4-diazepane, pyrrole, pyrrolidine, pyridonyl, imidazole, pyrazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyrimidine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, tetrazole, azepine, diazirine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, pyridazine, piperidine, piperazine, pyrrolidinone, ketopiperazine, furan, pyran, dioxole, 1,4-oxazepane, 1,4-oxazepine, oxazole, isoxazole, 2-isoxazoline, isoxazolidine, morpholine, oxirane, oxaziridine, 1,3-dioxolene, 1,3-dioxolane, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxaziridine, thiophene, thiopyran, thietan, thiazole, isothiazole, isothiazole, isothiazolidine, 1,2-oxathiolan, thiodiazole, thiopyran, 1,2-thiazine, 1,3-thiazole, 1,3-thiazine, 1,4-thiazine, thiadiazine or thiomorpholine.

thiazole, 1,3-thiazine, 1,4-thiazine, thiadiazine or thiomorpholine, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

- wherein, the aryl is phenyl that is unsubstituted or mono-, di- or trisubstituted
 independently of one another by R14, or
 - G is a direct bond, $-(CH_2)_m$ -, or $-(CH_2)_m$ -NR¹⁰-;
 - m is the integers zero, 1, 2, 3 or 4;

- M is 1. hydrogen,
 - 2. is $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
 - 3. is $-C(O)-N(R^{11})-R^{12}$.
- 35 6. wherein the heterocyclyl is azepane, azepine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, isothiazole, isoxazole, isoxazolidine, 2-

20

25

isoxazoline, ketomorpholine, ketopiperazine, morpholine, oxazole, [1,4]-oxazepane, 1,4-oxazepine, piperazine, piperazinone, piperidine, piperidinone, pyrazine, pyridazine, pyridazine, pyridazine, pyridazine, pyridazine, pyridine, pyridine, pyridine, pyridine, pyriolidine, pyrrolidine, tetrahydropyran, 1,4,5,6-tetrahydro-pyridazinyl, tetrazine, tetrazole, thiadiazole, thiazole, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

7. is (C_3-C_6) -cycloalkyl;

- 10 R³ and R⁴ are independent of one another are identical or different and are
 - 1) hydrogen,
 - 2) halogen,
 - -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 15 4) $-(C_1-C_3)$ -perfluoroalkyl,
 - 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - 6) $-(C_0-C_4)$ -alkylene-O-R19, wherein R19 is
 - a) hydrogen,
 - b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
 - c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - d) -CF₃, or
 - e) CHF₂,
 - 8) -CN,
 - 9) $-SO_s-R^{11}$, wherein s is 1 or 2,
 - 10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,
 - 11) $-(C_0-C_4)$ -alkylene-C(O)-R¹¹,
- 30 12) $-(C_0-C_4)$ -alkylene-C(0)-O-R¹¹,
 - 13) $-(C_0-C_4)$ -alkylene-C(O)-N(R¹¹)-R¹²,
 - 14) $-(C_0-C_4)$ -alkylene-N(R¹¹)-R¹²,
 - 15) $-NR^{10}-SO_2-R^{10}$,

- - (C_0-C_2) alkylene- $C(O)-O-(C_2-C_4)$ -alkylene- $O-C(O)-(C_1-C_4)$ -alkyl,
- 18) -C(O)-O- C(R15, R16)-O-C(O)-O-R17,
- 19) $-(C_0-C_2)$ alkylene- $C(O)-O-(C_2-C_4)$ -alkylene- $O-C(O)-O-(C_1-C_6)$ -alkyl,
- 20) -C(O)-O-C(R15, R16)-O-C(O)-R17,
- 5 -(C₀-C₄)-alkylene-(C₃-C₆)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - -(C_0 - C_3)-alkylene-O-CH₂-CF₂-CH₂-O-(C_0 - C_3)-alkyl, -(C_0 - C_3)-alkylene-O-CH₂-CF₂-CF₂-CH₂-O-(C_0 - C_3)-alkyl, or -(C_0 - C_3)-alkylene-O-CH₂-(C_1 - C_3)-perfluoroalkylene-CH₂-OH, or
- 10 26) a residue selected from the group consisting of

wherein Me is methyl, or

- two -OR19 residues and adjacent atoms through which they are attached form together a 5- or
 6- membered ring, that is unsubstituted or substituted one, two, three or four times by
 R13;
- 20 azetidine, 1,4-diazepane, dioxazole, dioxazine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, imidazole, imidazoline, iisothiazole, isothiazolidine, isothiazolidine, isothiazoline, isoxazole, isoxazoline, isoxazolidine, 2-isoxazoline, ketopiperazine, morpholine, [1,4]-oxazepane, 1,4-oxazepine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyrazolidine, pyrazolidine, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrrolidine, tetrahydropyridine, tetrazole, thiazole, thiadiazole, thiazolidine, thiazoline, thiomorpholine, thiophene, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R13;

R13 is fluorine, chlorine, -NO₂, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -N(R¹⁰)-S(O)₂-R¹⁰, -S-R¹⁰, -SO₂-R¹⁰, -S(O)₂-N(R¹⁰)-R²⁰, -C(O)-R¹⁰, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkoxy, phenyl, phenyloxy-, -O-CF₃, -(C₁-C₃)-perfluoroalkyl, -NH-C(O)-NH-R¹⁰, -(C₀-C₄)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-R17, -(C₁-C₄)-alkoxy-phenyl, -(C₀-C₄)-alkyl-C(O)-O-C(R15, R16)-O-C(O)-O-R17, -O-R15, -NH-C(O)-O-R¹⁰, or a residue selected from the group consisting of

wherein Me is methyl.

- 6. The compound according to claim 1, wherein,
- R0 as 1) is phenyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8,
 - 2) is a heterocyclyl selected out of the group indolyl, isoindolyl, benzofuranyl, benzothiophenyl, 1,3-benzodioxolyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, chromanyl, isochromanyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyridoimidazolyl, pyridopyridinyl, pyridopyrimidinyl, pyridinyl, purinyl and pteridinyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, or
 - is pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridazinyl and pyrazinyl, wherein said heterocyclyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R8, and in addition is substituted by a residue selected out of the group pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, furyl, 2-furyl, 3-furyl; thienyl, 2-thienyl, 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl,

10

5

15

20

25

isothiazolyl, triazolyl, tetrazolyl, pyridazinyl or pyrazinyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R8;

R8 is 1. F, Cl, Br, or I,

4. $-C(O)-NH_3$,

- 9. $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -OH or a methoxy residue, or
- 10. -O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen or a methoxy residue, provided that R8 is at least one halogen, -C(O)-NH₂ or -O-(C₁-C₈)-alkyl residue;
- Q is a direct bond, -C(O)-; $-SO_2$ or $-(C_1-C_6)$ -alkylen, $-(C_0-C_2)$ -alkylen--C(O)-NR¹⁰-;

 R^1 is hydrogen or $-(C_1-C_2)$ -alkyl;

15

20

10

5

 R^2 is a direct bond or as -(C₁-C₄)-alkylene is -(C₁-C₂)-alkylene, or

R¹-N-R²-V forms piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, thiadiazole or thiomorpholine, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;

R14 is fluoro, chlorine, $-(C_1-C_4)$ -alkyl or $-NH_2$;

25

30

V is 1. wherein the 3- to 7-membered cyclic residue is azaindolyl, 1H-pyrrolopyridyl, azetidine, azepine, aziridine, azirine, 1,4-diazepane, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, diazirine, 1,3-dioxolane, dioxazole, furan, imidazole, isoquinoline, isothiazole, isothiazolidine, isothiazoline, isoxazole, 2-isoxazoline, isoxazolidine, ketopiperazine, morpholine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, oxazole, 1,2-oxathiolan, piperidine, pyran, pyrazine, pyrazole, pyridazine, piperazine, pyridine, pyridone, pyrimidine, pyrrole, pyrrolidine, pyrrolidinone, quinazoline, quinoline, tetrazine, tetrazole, thiadiazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,3-thiazole, thietan, thiomorpholine, thiophene, thiopyran, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole or 1,2,4-triazole,

that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or

- 2. wherein, the aryl is phenyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14;
- G is a direct bond, $-(CH_2)_m$ -, or $-(CH_2)_m$ -NR¹⁰-;
- m is the integers zero, 1, 2, 3 or 4;

10

15

20

5

- M is 1. hydrogen,
 - 2. $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R14,
 - 6. wherein the heterocyclyl is 1,4-diazepane, ketomorpholine, thiophene, pyridazone, piperidine, piperazine, pyridine, pyrimidine, pyrrolidine, pyrrolidinone, pyridonyl, imidazole, pyridazine, pyrazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, tetrazine, tetrazole, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, azepine, ketopiperazine, oxazole, isoxazole, isoxazolidine, 2-isoxazoline, morpholine, thiazole, isothiazole, tetrahydropyran, 1,4,5,6-tetrahydropyridazinyl, thiadiazole or thiomorpholine, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R14, or 7.(C₃-C₆)-cycloalkyl;

 ${\rm R}^3$ and ${\rm R}^4$ are independent of one another are identical or different and are

25

- 1) hydrogen,
- 2) halogen,
- -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 4) -(C₁-C₃)-perfluoroalkyl,

30

- 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 6) $-(C_0-C_4)$ -alkylene-O-R19, wherein R19 is
 - a) hydrogen,
 - b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or

- c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- d) -CF₃, or
- e) $-CHF_2$,
- 5 8) -CN,
 - 9) $-SO_S-R^{11}$, wherein s is 1 or 2,
 - 10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,
 - 11) $-(C_0-C_4)$ -alkylene-C(O)-R¹¹,
 - 12) $-(C_0-C_4)$ -alkylene-C(O)-O-R¹¹,
- 10 13) $-(C_0-C_4)$ -alkylene-C(O)-N(R¹¹)-R¹²,
 - 14) $-(C_0-C_4)$ -alkylene-N(R¹¹)-R¹²,
 - 15) $-NR^{10}-SO_2-R^{10}$,
 - - (C_0-C_2) alkylene- $C(O)-O-(C_2-C_4)$ -alkylene- $O-C(O)-(C_1-C_4)$ -alkyl,
 - 18) -C(O)-O-C(R15, R16)-O-C(O)-R17,
- 15 $-(C_0-C_2)$ alkylene- $-(C_0-C_4)$ -alkylene- $-(C_0-C_6)$ -alkyl,
 - 20) -C(O)-O-C(R15, R16)-O-C(O)-O-R17,
 - -(C₀-C₃)-alkylene-(C₃-C₆)-cycloalkyl, or-(C₀-C₄)-alkylene-(C₃-C₆)-cycloalkyl, wherein cycloalkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 25) $-(C_0-C_3)$ -alkylene-O-CH₂-CF₂-CH₂-O-(C_0-C_3)-alkyl, $-(C_0-C_3)$ -alkylene-O-CH₂-CF₂-CF₂-CH₂-O-(C_0-C_3)-alkyl, or $-(C_0-C_3)$ -alkylene-O-CH₂-(C_1-C_3)-perfluoroalkylene-CH₂-OH, or
 - 26) a residue selected from the group consisting of

wherein Me is methyl;

10

25

R11 and R12 are independently of one another identical or different and are

- 1) hydrogen,
- -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 3) $-(C_0-C_6)$ -alkyl- (C_3-C_6) -cycloalkyl,
- 7) $-O-R^{17}$, or
- 8) -(C₀-C₆)-alkyl-(C₄-C₁₅)-heterocyclyl, wherein alkyl and heterocyclyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein heterocyclyl is selected out of the group azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine, or

R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, cyclopropyl, cyclobutyl, 4,5-dihydro-oxazole, imidazolidine, morpholine, (1,4)-oxazepane, 1,4-oxazepine, oxazolidine, piperidine, piperazine, pyrrolidine, tetrahydrothiophene, thiazolidine or thiomorpholine;

R13 is fluorine, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰, -N(R¹⁰)-R²⁰, -(C₃-C₆)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -S-R¹⁰, -SO₂-R¹⁰, -(C₁-C₃)-perfluoroalkyl, or a residue selected from the group consisting of

wherein Me is methyl;

 R^{10} and R^{20} are independently of one another hydrogen, -(C₁-C₄)-alkyl or -(C₁-C₃)-perfluoroalkyl;

 R^{15} and R^{16} are independently of one another hydrogen, -(C_1 - C_4)-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, that is unsubstituted one to three times by R^{10} .

- 5 7. The compound according to claim 1, wherein,
 - R0 as 1. is phenyl, that is unsubstituted or mono- or disubstituted independently of one another by R8,
- is pyridyl, that is unsubstituted or mono- or disubstituted independently of one another by R8, or
- is thienyl, thiadiazolyl, isoxazolyl or thiazolyl, that is substituted by a residue selected from the group consisting of thienyl, 2-thienyl and 3-thienyl, wherein said residue is unsubstituted or mono- or disubstituted independently of one another by R8;

R8 is F, Cl, Br, -OCH₃, -C(O)-NH₂ or -O-CF₃;

Q is a direct bond, -C(O)-; -SO₂-, -CH₂-C(O)-NH-, methylene or ethylene;

R¹ is hydrogen;

25

35

R² is a direct bond or as -(C₁-C₄)-alkylene is methylene, or

R¹-N-R²-V forms azetidine, pyrrolidine, piperidine and piperazine;

R14 is fluorine, chlorine, methyl, ethyl or -NH₂;

V is

1. azaindolyl, 1H-pyrrolopyridyl, azetidine, 1,4-diazepane, isoxazole, isoquinoline, piperazine, piperidine, pyrazine, pyridazine, pyrimidine, pyrrolidine, quinazoline, quinoline or tetrahydropyrane, that is unsubstituted or mono- or disubstituted independently of one another by R14, or

2. phenyl, that is unsubstituted or mono- or disubstituted independently of one

another by R14;

G is a direct bond, $-(CH_2)_{m}$, or $-(CH_2)_{m}$ -NR¹⁰-;

5 m is the integers zero, 1 or 2;

M is hydrogen, (C_2-C_4) -alkyl, azepanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, imidazolyl, ketomorpholinyl, morpholinyl, [1,4]oxazepanyl, piperidinyl, piperidonyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidyl, pyrrolidinyl, 1,4,5,6-tetrahydropyridazinyl, or tetrahydropyranyl, that are unsubstituted or mono- or disubstituted independently of one another by R14;

 ${\rm R}^3$ and ${\rm R}^4$ are independent of one another are identical or different and are

- 1) hydrogen,
- 15 2) fluorine, chlorine,

10

20

- -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- 4) -(C₁-C₃)-perfluoroalkyl,
- 5) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - 6) $-(C_0-C_2)$ -alkylene-O-R19, wherein R19 is
 - a) hydrogen,
 - b) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
 - c) phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - d) -CF3, or
 - e) $-CHF_2$,
 - 8) -CN,
- 30 9) $-SO_s-R^{11}$, wherein s is 1 or 2,
 - 10) $-SO_t-N(R^{11})-R^{12}$, wherein t is 1 or 2,
 - 11) $-(C_0-C_4)$ -alkylene-C(O)-R¹¹,
 - 12) $-(C_0-C_4)$ -alkylene-C(O)-O-R¹¹,
 - 13) $-(C_0-C_4)$ -alkylene- $C(O)-N(R^{11})-R^{12}$,

- 14) $-(C_0-C_4)$ -alkylene-N(R¹¹)-R¹²,
- 15) -NR¹⁰-SO₂-R¹⁰,
- - (C_0-C_2) alkylene- $C(O)-O-(C_2-C_4)$ -alkylene- $O-C(O)-(C_1-C_4)$ -alkyl,
- 18) -C(O)-O-C(R15, R16)-O-C(O)-R17,
- - 20) -C(O)-O-C(R15, R16)-O-C(O)-O-R17,
 - -(C₀-C₃)-alkylene-(C₃-C₆)-cycloalkyl, or -(C₀-C₄)-alkylene-(C₃-C₆)-cycloalkyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
- wherein the -(C₀-C₄)-alkylene is absent and the het is pyridyl, or thiazolyl, that is unsubstituted or mono-, di- or trisubstituted independently of one another by R13, or
 - $\label{eq:condition} \begin{tabular}{ll} -(C_0-C_3)-alkylene-O-CH_2-CF_2-CH_2-O-(C_0-C_3)-alkylene-O-CH_2-CF_2-CF_2-CH_2-O-(C_0-C_3)-alkylene-O-CH_2-(C_1-C_3)-alkylene-O-CH$
- 15 26) a residue selected from the group consisting of

wherein Me is methyl;

- R11 and R12 are independently of one another identical or different and are
 - 1) hydrogen,
 - 2) -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R13,
 - 3) $-(C_0-C_6)$ -alkyl- (C_3-C_6) -cycloalkyl,
 - 7) $-O-R^{17}$, or

25

8) -(C₀-C₆)-alkyl-heterocyclyl, wherein alkyl and heterocyclyl independently from

one another are unsubstituted or mono-, di- or trisubstituted by R13 and wherein heterocyclyl is azetidine, imidazolidine, morpholine, (1,4)-oxazepane or pyrrolidine, or

R11 and R12 together with the nitrogen atom to which they are bonded form azetidine, imidazolidine, morpholine, (1,4)-oxazepane, 1,4-oxazepine, piperazine, piperidine, pyrrolidine or thiomorpholine;

R13 is fluorine, chlorine, -CN, =O, -OH, -CF₃, -C(O)-O-R¹⁰, -C(O)-N(R¹⁰)-R²⁰,

-N(R¹⁰)-R²⁰, -(C₃-C₆)-cycloalkyl, -(C₀-C₃)-alkylene-O-R¹⁰, -Si-(CH₃)₃, -S-R¹⁰, -SO₂-R¹⁰, -(C₁-C₄)-alkyl, -(C₁-C₃)-perfluoroalkyl, or a residue selected from the group consisting of

wherein, Me is methyl;

 R^{10} and R^{20} are independently of one another hydrogen, -(C1-C4)-alkyl or -(C1-C3)-perfluoroalkyl; and

- 20 R^{15} and R^{16} are independently of one another hydrogen, -(C_1 - C_4)-alkyl, or together form cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, wherein each ring is unsubstituted or substituted one to three times by R^{10} .
- 8. The compound according to claim 1, wherein, formula I is a compound of the formula Ia, 25

9. The compound according to claim 1, wherein, formula I is a compound of the formula Ib,

5 10. The compound according to claim 1, wherein, formula I is a compound of the formula Ic,

11. The compound according to claim 1, wherein, formula I is a compound of the formula Id,

$$\begin{array}{c|c}
R^1 \\
N-R^2-V-G-N \\
N & R3
\end{array}$$
(Id)

10

12. The compound according to claim 1, which is:

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

15

20


1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

5-Chloro-3-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-phenyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

| | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-ethyl-5-methyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
|----|---|
| 5 | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-ethyl-5-methyl-1H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 10 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-iodo-5-methyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-iodo-5-methyl-1H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 15 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-methoxymethyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-methoxymethyl-1H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 20 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-cyclopropyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 25 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2,6-difluoro-phenyl)-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 20 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-cyclopentyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 30 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2-methoxy-ethyl)-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| · | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2,6-dichloro-phenyl)-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 35 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-isopropyl-3H-imidazole-4- carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |

| | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-pyridin-2-yl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
|----|--|
| 5 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-2-phenyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-2-phenyl-1H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 10 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-pyridin-3-yl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 15 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2-methyl-thiazol-4-yl)-3H- imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 13 | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2-methyl-thiazol-4-yl)-1H- imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 20 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-ethanesulfonyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-3H-imidazole-2,4- dicarboxylic acid 2-amide 4-[(1-isopropyl-piperidin-4-yl)-amide]; |
| 25 | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-1H-imidazole-2,4- dicarboxylic acid 2-amide 4-[(1-isopropyl-piperidin-4-yl)-amide]; |
| 30 | 2-Bromo-3-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 30 | 2-Bromo-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-methyl-1H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 35 | 2-(4-Chloro-phenyl)-1-[5-(5-chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |



| | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-2,4-dicarboxylic acid 4-amide 2-[(1-isopropyl-piperidin-4-yl)-amide]; |
|-----|---|
| 5 | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-2,4-dicarboxylic acid 4-[(2-hydroxy-ethyl)-methyl-amide] 2-[(1-isopropyl-piperidin-4-yl)-amide; |
| | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-(3-hydroxy-azetidine-1-carbonyl)-1H-imidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 10 | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-2,4-dicarboxylic acid 4-dimethylamide 2-[(1-isopropyl-piperidin-4-yl)-amide]; |
| 15 | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-imidazole-4-carboxylic acid cyclopropylmethyl ester; |
| | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-imidazole-4-carboxylic acid tert-butoxycarbonylmethyl ester; |
| 20 | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-2,4-dicarboxylic acid 4-[(2-hydroxy-ethyl)-amide] 2-[(1-isopropyl-piperidin-4-yl)-amide; |
| | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-4-(3-methoxy-azetidine-1-carbonyl)-1H-imidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 25 | 3-[1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(1-isopropyl-piperidin-4-ylcarbamoyl)-1H-imidazol-4-yl]-propionic acid methyl ester; |
| | 1-(3-Methoxy-benzyl)-1H-imidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide, |
| 30 | 1-(3-Methoxy-benzyl)-1H-imidazole-2-carboxylic acid (1-isopropyl-piperidin-4-ylmethyl)-amide; |
| 0.5 | 1-(3-chloro-benzyl)-1H-imidazole-2-carboxylic acid (1-isopropyl-piperidin-4-ylmethyl)-amide; |
| 35 | 1-(3,4-Difluoro-benzyl)-1H-imidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |

| | 1-(3-Fluoro-benzyl)-1H-imidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
|----|---|
| 5 | [1-(3-Methoxy-benzyl)-1H-imidazol-2-yl]-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-methanone; |
| J | 1-(3-Methoxy-benzyl)-1H-imidazole-2-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4]bipyridinyl-4-ylmethyl)-amide; |
| 10 | 1-(3-Methoxy-benzyl)-1H-imidazole-2-carboxylic acid (1-pyridin-4-yl-azetidin-3-ylmethyl)-amide; |
| | 1-(3-Methoxy-benzyl)-1H-imidazole-2-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-amide; |
| 15 | 1-(3-methoxy-benzyl)-1H-imidazole-2-carboxylic acid (1-pyridin-4-yl-azetidin-3-yl)- amide; |
| | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 20 | 1-[2-(4-Chloro-phenyl)-ethyl]-1H-imidazole-2-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |
| 25 | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-2-carboxylic acid (1-isopropyl-azetidin-3-ylmethyl)-amide; |
| 25 | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-2-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4]bipyridinyl-4-ylmethyl)-amide; |
| 30 | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-2-carboxylic acid (1-isopropyl-piperidin-4-ylmethyl)-amide; |
| | 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-1H-imidazole-2-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-amide; |
| 35 | 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-[2-(2-methoxy-ethoxy)-ethoxymethyl]-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; |

1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-methoxymethyl-1H-imidazole-4-carboxylic acid (2'-methanesulfonyl-biphenyl-4-yl)-amide;

3-[2-(4-Chloro-phenyl)-ethyl]-2-[2-(2-methoxy-ethoxy)-ethoxymethyl]-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(2-methoxy-ethoxymethyl)-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide;

3-[(5-Chloro-pyridin-2-ylcarbamoyl)-methyl]-2-(2-methoxy-ethoxymethyl)-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide; or

3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-2-(perhydro-1,4-oxazepine-4-carbonyl)-3H-imidazole-4-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide.

15

5

13. A process for the preparation of a compound according to claim 1 comprising condensing a compound of the formula 29 with a compound of the formula HR⁸ to give a compound of the formula 30 and converting the compound of the formula 30 into the compound of the formula I,

20

25

wherein the residue R^8 ' has the donation of $-N(R^1)-R^2-V-G-M$ as indicated in claims 1 to 12, but where in R^8 ' functional groups can also be present in the form of groups that are subsequently transformed into the final functional groups present in $-N(R^1)-R^2-V-G-M$, and where the residue R^{53} denotes the group $-Q-R^0$, where the groups Q and R^0 have the definitions as in the compound of formula (I) or can denote a group which is subsequently

10

transformed into the group $-Q-R^0$, and where the group $-C(O)-R^{52}$ can be a carboxylic acid group or derivatives thereof, and where the groups R^{1a} and R^{1b} in the formulae 29 and 30 have the corresponding definitions of R^3 and R^4 in formula I as defined in claims 1 to 12 or functional groups in them can also be present in protected form or in the form of precursor groups.

- 14. A pharmaceutical preparation, comprising at least one compound of the formula I according to claim 1 in all its stereoisomeric forms and mixtures thereof in any ratio and/or its physiologically tolerable salts and a pharmaceutically acceptable carrier.
- 15. A method of inhibiting the activity of factor Xa and/or factor VIIa comprising contacting an inhibitory amount of a compound according to claim 1 with a composition containing factor Xa and/or factor VIIa to influence blood coagulation.
- 16. A method of inhibiting the activity of factor Xa and/or factor VIIa comprising contacting an inhibitory amount of a compound according to claim 1 with a composition containing factor Xa and/or factor VIIa to influence fibrinolysis.
- 17. A method for treating a patient suffereing from, or subject to, a disease state selected from 20 abnormal thrombus formation, acute myocardial infarction, cardiovascular disorders, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy or percutaneous, transluminal coronary angioplasty (PTCA), transient ischemic attacks, stroke, intermittent claudication, bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing, restenosis post coronary or venous angioplasty, maintenance of vascular access patency in 25 long-term hemodialysis patients, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee or hip surgery, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulatopathy occurring in vascular systems during septic shock, viral infections or cancer, or reducing an inflammatory response, 30 fibrinolysis, or treatment of coronary heart disease, myocardial infarction, angina pectoris, vascular restenosis, for example restenosis following angioplasty like PTCA, adult respiratory distress syndrome, multi-organ failure and disseminated intravascular clotting disorder, deep vein and proximal vein thrombosis, which can occur following surgery.